$125 | Single User
$250 | Site License
$375 | Global License

GlaxoSmithKline Plc (GSK) - Financial and Strategic SWOT Analysis Review
[Published by Global Data]

Published by Global Data: 28 Mar 2019 | 231981 | In Stock
Related Topics: GlaxoSmithKline

Introduction

GlaxoSmithKline Plc (GSK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.

- Corporate strategy – Analyst’s summarization of the company’s business strategy.

- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.

- Company history – Progression of key events associated with the company.

- Major products and services – A list of major products, services and brands of the company.

- Key competitors – A list of key competitors to the company.

- Key employees – A list of the key executives of the company.

- Executive biographies – A brief summary of the executives’ employment history.

- Key operational heads – A list of personnel heading key departments/functions.

- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities – A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

GlaxoSmithKline Plc (GSK) is a healthcare company that focuses on the development, manufacture and commercialization of pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of HIV, respiratory, cancer, immuno-inflammation, anti-virals, central nervous system (CNS), metabolic, cardiovascular and urogenital, anti-bacterials, dermatology and rare diseases. The company offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK’s vaccine portfolio cover various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide. GSK is headquartered in Brentford, Middlesex, the UK.

GlaxoSmithKline Plc Key Recent Developments

Mar 21,2019 GlaxoSmithKline targets regulatory filings by year end for antiBCMA drug GSK2857916 in multiple myeloma httpswww.firstwordpharma.comnode1630817Â $GSK

Mar 18,2019 Two-drug combos using popular calcium channel blocker show superiority in lowering blood pressure

Mar 11,2019 NEW GENETIC DATA FROM REGENERON AND GSK ON 50,000 UK BIOBANK PARTICIPANTS MADE AVAILABLE TO GLOBAL HEALTH RESEARCH COMMUNITY

Mar 11,2019 New genetic data from Regeneron and GSK on 50,000 UK Biobank participants made available to global health research community

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents
for GlaxoSmithKline Plc (GSK) - Financial and Strategic SWOT Analysis Review [Published by Global Data]

  • Table of Contents

    Table of Contents

    List of Tables

    List of Figures

    Section 1 - About the Company

    GlaxoSmithKline Plc - Key Facts

    GlaxoSmithKline Plc - Key Employees

    GlaxoSmithKline Plc - Key Employee Biographies

    GlaxoSmithKline Plc - Major Products and Services

    GlaxoSmithKline Plc - History

    GlaxoSmithKline Plc - Company Statement

    GlaxoSmithKline Plc - Locations And Subsidiaries

    Head Office

    Other Locations & Subsidiaries

    Joint Venture

    Section 2 – Company Analysis

    Company Overview

    GlaxoSmithKline Plc - Business Description

    Business Segment: Consumer Healthcare

    Overview

    Performance

    Key Stats

    Business Segment: Pharmaceuticals

    Overview

    Performance

    Key Stats

    Business Segment: Vaccines

    Overview

    Performance

    Key Stats

    Geographical Segment: Rest of World

    Performance

    Geographical Segment: The UK

    Performance

    Geographical Segment: The US

    Performance

    R&D Overview

    GlaxoSmithKline Plc - Corporate Strategy

    GlaxoSmithKline Plc - SWOT Analysis

    SWOT Analysis - Overview

    GlaxoSmithKline Plc - Strengths

    GlaxoSmithKline Plc - Weaknesses

    GlaxoSmithKline Plc - Opportunities

    GlaxoSmithKline Plc - Threats

    GlaxoSmithKline Plc - Key Competitors

    Section 3 – Company Financial Ratios

    Financial Ratios - Capital Market Ratios

    Financial Ratios - Annual Ratios

    Performance Chart

    Financial Performance

    Financial Ratios - Interim Ratios

    Financial Ratios - Ratio Charts

    Section 4 – Company’s Lifesciences Financial Deals and Alliances

    GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

    GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

    GlaxoSmithKline Plc, Recent Deals Summary

    Section 5 – Company’s Recent Developments

    Mar 21, 2019: GlaxoSmithKline targets regulatory filings by year end for antiBCMA drug GSK2857916 in multiple myeloma httpswww.firstwordpharma.comnode1630817Â $GSK

    Mar 18, 2019: Two-drug combos using popular calcium channel blocker show superiority in lowering blood pressure

    Mar 11, 2019: NEW GENETIC DATA FROM REGENERON AND GSK ON 50,000 UK BIOBANK PARTICIPANTS MADE AVAILABLE TO GLOBAL HEALTH RESEARCH COMMUNITY

    Mar 11, 2019: New genetic data from Regeneron and GSK on 50,000 UK Biobank participants made available to global health research community

    Mar 04, 2019: California Life Sciences Association (CLSA) adds GlaxoSmithKline and Blade Therapeutics to Board

    Feb 27, 2019: Study Identifies Predictors of Psychiatric Events During Drug-Assisted Smoking Cessation

    Feb 18, 2019: GSK to divest Chiron Behring Vaccines to Bharat Biotech

    Feb 06, 2019: GSK signs .2bn immunotherapy deal with Merck

    Feb 06, 2019: GSK delivers sales, earnings and cash flow growth in 2018

    Feb 05, 2019: Wellcome commits £10 million to DNDi to develop new generation of oral drugs to treat leishmaniasis

    Section 6 – Appendix

    Methodology

    Ratio Definitions

    About GlobalData

    Contact Us

    Disclaimer

List Of Tables
in GlaxoSmithKline Plc (GSK) - Financial and Strategic SWOT Analysis Review [Published by Global Data]

List of Tables

GlaxoSmithKline Plc, Key Facts

GlaxoSmithKline Plc, Key Employees

GlaxoSmithKline Plc, Key Employee Biographies

GlaxoSmithKline Plc, Major Products and Services

GlaxoSmithKline Plc, History

GlaxoSmithKline Plc, Other Locations

GlaxoSmithKline Plc, Subsidiaries

GlaxoSmithKline Plc, Joint Venture

GlaxoSmithKline Plc, Key Competitors

GlaxoSmithKline Plc, Ratios based on current share price

GlaxoSmithKline Plc, Annual Ratios

GlaxoSmithKline Plc, Annual Ratios (Cont...1)

GlaxoSmithKline Plc, Annual Ratios (Cont...2)

GlaxoSmithKline Plc, Interim Ratios

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

GlaxoSmithKline Plc, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List Of Figures, Charts and Diagrams
in GlaxoSmithKline Plc (GSK) - Financial and Strategic SWOT Analysis Review [Published by Global Data]

List of Figures

GlaxoSmithKline Plc, Performance Chart (2014 - 2018)

GlaxoSmithKline Plc, Ratio Charts

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

Additional Details

Publisher

Global Data

Publisher Information

Reference

231981 |

Number of Pages

94

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
GlaxoSmithKline Partnering Deals and Alliances 2010 to 2016
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering...
01 Oct 2016 by Current Partnering USD $1,495 More Info
GlaxoSmithKline K.K. - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryGlaxoSmithKline K.K. (GSK Japan) a subsidiary of GlaxoSmithKline Plc is a pharmaceutical comp...
10 Mar 2016 by Global Data USD $250 More Info
GlaxoSmithKline Pharmaceuticals Limited (GLAXO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryGlaxoSmithKline Pharmaceuticals Limited (GSK India) is a pharmaceutical company that manufact...
04 Mar 2016 by Global Data USD $250 More Info
GlaxoSmithKline Plc (GSK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryGlaxoSmithKline plc (GSK) is a healthcare company, which focuses on the development, manufact...
04 Mar 2016 by Global Data USD $250 More Info
GlaxoSmithKline Plc (GSK) - Medical Equipment - Deals and Alliances Profile
SummaryGlaxoSmithKline plc (GSK) is a healthcare company, which focuses on the development, manufact...
24 Feb 2016 by Global Data USD $250 More Info
GlaxoSmithKline Consumer Nigeria PLC (GLAXOSMITH) - Financial and Strategic SWOT Analysis Review
SummaryGlaxoSmithKline Consumer Nigeria PLC (GlaxoSmithKline Consumer Nigeria) a subsidiary of Glaxo...
09 Jan 2016 by Global Data USD $300 More Info
GlaxoSmithKline Consumer Nigeria PLC (GLAXOSMITH) - Financial and Strategic SWOT Analysis Review
SummaryGlaxoSmithKline Consumer Nigeria PLC (GlaxoSmithKline Consumer Nigeria) a subsidiary of Glaxo...
08 Nov 2015 by Global Data USD $300 More Info
Physician Views: Is GlaxoSmithKline's BRAF/MEK combo making headway in V600 mutation-positive melanoma patients?
Scope Although the clinical promise of cancer immunotherapies looks poised to see these products gai...
22 Jul 2014 by FirstWord Pharma USD $695 More Info
Physician Views: Assessing the launch of GlaxoSmithKline's Breo Ellipta
Scope It remains early in the launch, but available evidence suggests that GlaxoSmithKline's Breo El...
21 Jan 2014 by FirstWord Pharma USD $695 More Info
Physician Views: Can GlaxoSmithKline strike early with Anoro? / What role will dosing, inhaler type play in uptake of LAMA/LABA combinations for COPD?
ScopeThis year looks set to be one of notable evolution for the US chronic obstructive pulmonary dis...
01 Aug 2013 by FirstWord Pharma USD $695 More Info

This report is published by Global Data

Download Free Report Summary PDF

GlaxoSmithKline Plc (GSK) - Financial and Strategic SWOT Analysis Review [Published by Global Data] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • 360i Research
  • 99Strategy
  • Allied Market Research
  • Asia Market Information & Development Co.
  • Azoth Analytics
  • BioInformant
  • Black Swan Analysis
  • Canadean
  • CBR Pharma Insights
  • CRI
  • Current Analysis
  • Current Partnering
  • Daedal Research
  • Data bridge
  • Delve Insight
  • DPI Research
  • FirstWord Pharma
  • Future Market Insights
  • GBI Research
  • Global Data
  • Global Markets Direct
  • Global Research and Data Services GRDS
  • GMR Data
  • HeyReport
  • HongChun
  • HTStec
  • ICD Research
  • iGATE Research
  • IMARC
  • Industry ARC
  • Inkwood Research
  • IQ4I
  • Jain PharmaBiotech
  • Kelly Scientific
  • La Merie
  • Lifescience Intellipedia
  • LP Information
  • Market Data Forecast
  • Market Research Future
  • Marketline
  • MarketsandMarkets
  • McDerson
  • MedMarket Diligence
  • Meticulous Research
  • MicroMarketMonitor
  • MIReports
  • Mordor Intelligence LLC
  • MP Advisors
  • Occams Business Research
  • Prof Research
  • Progressive Markets
  • ProGrow Pharma Partners
  • Renub
  • Research Impact
  • RNCOS
  • Rockville Research
  • S&P Consulting
  • StratisticsMRC
  • The Business Research Company
  • Triton Market Research
  • Venture Planning Group (VPG)